TG Therapeutics, Inc. (TGTX) 10-Year Financial Performance & Capital Metrics

TGTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.Show more

Revenue $329M +40.8%
EBITDA $42M +100.5%
Net Income $23M +84.5%
EPS (Diluted) 0.15 +75.8%
Gross Margin 88.3% -6.0%
EBITDA Margin 12.83% +42.4%
Operating Margin 12.74% +44.3%
Net Margin 7.11% +31.1%
ROE 12.21% +5.6%
ROIC 13.25% -6.8%
Debt/Equity 1.14 +65.3%
Interest Coverage 1.75 +6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 364.6%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Expensive at 22.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y115.49%

5Y364.59%

3Y266.39%

TTM30.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-36.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-38.15%

ROCE

10Y Avg-122.62%

5Y Avg-48.95%

3Y Avg-25.05%

Latest10.99%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	152.38K	152.38K	152.38K	152K	152K	152K	6.69M	2.79M	233.66M	329M
Revenue Growth %	0%	0%	0%	-0%	0%	0%	43.01%	-0.58%	82.9%	0.41%
Cost of Goods Sold+	0	62.96K	82.36K	88K	0	0	790K	265K	14.13M	38.49M
COGS % of Revenue	-	0.41%	0.54%	0.58%	-	-	0.12%	0.1%	0.06%	0.12%
Gross Profit+	152.38K	89.42K	70.03K	64K	152K	152K	5.9M	2.52M	219.53M	290.52M
Gross Margin %	1%	0.59%	0.46%	0.42%	1%	1%	0.88%	0.9%	0.94%	0.88%
Gross Profit Growth %	0%	-0.41%	-0.22%	-0.09%	1.38%	0%	37.81%	-0.57%	86.12%	0.32%
Operating Expenses+	63.33M	79.12M	118.86M	174.55M	169.21M	273.75M	350.67M	220.84M	198.9M	248.59M
OpEx % of Revenue	415.62%	519.23%	780.05%	1148.37%	1113.2%	1800.96%	52.42%	79.29%	0.85%	0.76%
Selling, General & Admin	15.63M	9.89M	16.33M	15.16M	15.03M	107.85M	128.09M	95.48M	122.71M	154.3M
SG&A % of Revenue	102.54%	64.9%	107.17%	99.74%	98.86%	709.54%	19.15%	34.29%	0.53%	0.47%
Research & Development	43.45M	66.49M	96.89M	153.79M	154.18M	165.9M	222.58M	125.35M	76.19M	94.29M
R&D % of Revenue	285.11%	436.34%	635.82%	1011.8%	1014.34%	1091.42%	33.28%	45.01%	0.33%	0.29%
Other Operating Expenses	1.03M	393.2K	-58.74K	61K	0	0	0	0	0	0
Operating Income+	-63.18M	-78.97M	-118.71M	-174.4M	-169.06M	-273.59M	-344.77M	-218.32M	20.63M	41.93M
Operating Margin %	-414.62%	-518.23%	-779.05%	-1147.37%	-1112.2%	-1799.96%	-51.54%	-78.39%	0.09%	0.13%
Operating Income Growth %	-0.13%	-0.25%	-0.5%	-0.47%	0.03%	-0.62%	-0.26%	0.37%	1.09%	1.03%
EBITDA+	-63.16M	-78.91M	-118.63M	-174.31M	-168.77M	-273.22M	-344.28M	-217.8M	21.06M	42.21M
EBITDA Margin %	-414.52%	-517.82%	-778.51%	-1146.79%	-1110.35%	-1797.5%	-51.47%	-78.21%	0.09%	0.13%
EBITDA Growth %	-0.13%	-0.25%	-0.5%	-0.47%	0.03%	-0.62%	-0.26%	0.37%	1.1%	1%
D&A (Non-Cash Add-back)	15.45K	62.96K	82.36K	88K	282K	374K	494K	515K	423K	280K
EBIT	-63.18M	-78.97M	-117.63M	-172.6M	-167.58M	-273.05M	-342.46M	-213.62M	25.68M	49.62M
Net Interest Income+	-798.08K	323K	-845K	-877K	-5.29M	-6.33M	-5.64M	-10.19M	-12.62M	-24.03M
Interest Income	174.65K	323.03K	294.48K	857K	0	0	0	0	0	0
Interest Expense	972.74K	0	1.14M	1.73M	5.29M	6.33M	5.64M	10.19M	12.62M	24.03M
Other Income/Expense	231.37K	716K	235.99K	918K	-3.82M	-5.79M	-3.33M	-5.5M	-7.57M	-16.34M
Pretax Income+	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	13.06M	25.59M
Pretax Margin %	-413.1%	-513.53%	-777.5%	-1141.33%	-1137.31%	-1838.03%	-52.04%	-80.36%	0.06%	0.08%
Income Tax+	-231.37K	-716.23K	-235.74K	-918K	0	0	0	0	390K	2.21M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	0.91%
Net Income+	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	12.67M	23.38M
Net Margin %	-413.1%	-513.53%	-777.5%	-1141.33%	-1137.31%	-1838.03%	-52.04%	-80.36%	0.05%	0.07%
Net Income Growth %	-0.13%	-0.24%	-0.51%	-0.46%	0%	-0.62%	-0.25%	0.36%	1.06%	0.85%
Net Income (Continuing)	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	12.67M	23.38M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.38	-1.60	-1.91	-2.30	-1.96	-2.42	-2.63	-1.46	0.09	0.15
EPS Growth %	0.16%	-0.16%	-0.19%	-0.2%	0.15%	-0.23%	-0.09%	0.44%	1.06%	0.76%
EPS (Basic)	-1.38	-1.60	-1.91	-2.30	-1.96	-2.42	-2.63	-1.46	0.09	0.16
Diluted Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	148.51M	160.34M
Basic Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	141.96M	145.32M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	86.87M	50.86M	93.32M	79.03M	149.15M	611.74M	330.96M	168.27M	317.94M	566.36M
Cash & Short-Term Investments	102.42M	44.97M	84.83M	68.81M	140.44M	605.43M	314.76M	161.68M	217.51M	311M
Cash Only	55.06M	25.03M	56.72M	41.96M	112.64M	553.44M	298.89M	102.3M	92.93M	179.89M
Short-Term Investments	22.17M	19.85M	28M	26.85M	27.8M	51.99M	15.88M	59.37M	124.58M	131.11M
Accounts Receivable	186.02K	83.85K	108.47K	95K	0	0	1.39M	0	51.09M	129.19M
Days Sales Outstanding	445.58	200.85	259.81	228.13	-	-	75.79	-	79.81	143.32
Inventory	-16.04M	5.59M	7.95M	9.69M	0	0	0	0	39.82M	110.46M
Days Inventory Outstanding	-	32.44K	35.22K	40.2K	-	-	-	-	1.03K	1.05K
Other Current Assets	308.33K	216.4K	328.32K	344K	611K	1.08M	2.88M	2.36M	5.34M	15.72M
Total Non-Current Assets+	26.6M	3.92M	4.06M	4.58M	13.86M	13.9M	48.66M	25.3M	11.64M	11.33M
Property, Plant & Equipment	47.12K	2.37M	2.68M	2.54M	11.81M	11.84M	11.07M	10.82M	8.05M	7.15M
Fixed Asset Turnover	3.23x	0.06x	0.06x	0.06x	0.01x	0.01x	0.60x	0.26x	29.03x	46.01x
Goodwill	799.39K	799.39K	799.39K	799K	799K	799K	799K	799K	799K	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	25M	583.21K	587.29K	1.24M	0	0	35.53M	12.4M	0	808K
Other Non-Current Assets	750.33K	747.58K	587.29K	1.24M	1.25M	1.26M	1.26M	1.27M	2.79M	3.37M
Total Assets+	113.47M	54.78M	97.38M	83.62M	163.01M	625.64M	379.63M	193.57M	329.59M	577.69M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.02x	0.01x	0.71x	0.57x
Asset Growth %	0.31%	-0.52%	0.78%	-0.14%	0.95%	2.84%	-0.39%	-0.49%	0.7%	0.75%
Total Current Liabilities+	10.53M	16.88M	27.96M	38.85M	84.45M	87.55M	65.38M	53.2M	53.72M	90.68M
Accounts Payable	9.35M	15.27M	25.88M	36.38M	0	0	0	0	0	0
Days Payables Outstanding	-	88.51K	114.69K	150.88K	-	-	-	-	-	-
Short-Term Debt	211.55K	68.88K	127.61K	67K	0	22.18M	975K	0	0	0
Deferred Revenue (Current)	152.38K	152.38K	152.38K	152K	0	0	0	0	152K	1000K
Other Current Liabilities	0	0	0	0	82.83M	63.71M	62.97M	51.62M	52.12M	78.11M
Current Ratio	8.25x	3.01x	3.34x	2.03x	1.77x	6.99x	5.06x	3.16x	5.92x	6.25x
Quick Ratio	9.77x	2.68x	3.05x	1.78x	1.77x	6.99x	5.06x	3.16x	5.18x	5.03x
Cash Conversion Cycle	-	-55.88K	-79.21K	-110.46K	-	-	-	-	-	-
Total Non-Current Liabilities+	1.37M	2.04M	2.43M	20.73M	39.95M	18.74M	77.09M	81.78M	115.36M	264.65M
Long-Term Debt	0	0	0	0	28.97M	7.72M	66.79M	71.14M	100.12M	244.43M
Capital Lease Obligations	0	0	0	0	10.22M	10.41M	9.85M	10.34M	9.23M	8.13M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	816.26K	1.36M	19.81M	0	0	0	0	0	0
Total Liabilities	113.47M	54.78M	97.38M	59.58M	124.4M	106.29M	142.48M	134.99M	169.09M	355.33M
Total Debt+	211.55K	68.88K	127.61K	67K	40.8M	41.98M	79.05M	83.06M	110.8M	253.72M
Net Debt	-54.85M	-24.96M	-56.59M	-41.89M	-71.83M	-511.46M	-219.84M	-19.24M	17.86M	73.83M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	1.06x	0.08x	0.33x	1.42x	0.69x	1.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	5.26x	6.01x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	0.85x	1.75x
Interest Coverage	-64.95x	-	-104.18x	-100.58x	-31.98x	-43.23x	-61.15x	-21.42x	1.64x	1.75x
Total Equity+	101.57M	35.87M	66.99M	24.04M	38.62M	519.35M	237.15M	58.59M	160.5M	222.36M
Equity Growth %	0.27%	-0.65%	0.87%	-0.64%	0.61%	12.45%	-0.54%	-0.75%	1.74%	0.39%
Book Value per Share	2.23	0.73	1.08	0.32	0.44	4.50	1.79	0.43	1.08	1.39
Total Shareholders' Equity	101.57M	35.87M	66.99M	24.04M	38.62M	519.35M	237.15M	58.59M	160.5M	222.36M
Common Stock	54.09K	56.82K	73.18K	84K	109K	141K	143K	146K	151K	156K
Retained Earnings	-158.13M	-236.39M	-354.86M	-528.35M	-701.22M	-980.6M	-1.33B	-1.53B	-1.55B	-1.53B
Treasury Stock	-234.34K	-234.34K	-234.34K	-234K	-234K	-234K	-234K	-234K	-234K	-8.99M
Accumulated OCI	6	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-44.69M	-61.59M	-93.76M	-128.93M	-132.81M	-214.51M	-295.63M	-176.17M	-31.41M	-40.52M
Operating CF Margin %	-293.28%	-404.19%	-615.32%	-848.19%	-873.72%	-1411.23%	-44.2%	-63.26%	-0.13%	-0.12%
Operating CF Growth %	-0.27%	-0.38%	-0.52%	-0.38%	-0.03%	-0.62%	-0.38%	0.4%	0.82%	-0.29%
Net Income	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-198.34M	12.67M	23.38M
Depreciation & Amortization	15.45K	62.96K	82.36K	88K	282K	374K	494K	515K	423K	280K
Stock-Based Compensation	15.7M	7.51M	15.95M	12.89M	11.34M	80.29M	61.27M	19.18M	37.93M	42.54M
Deferred Taxes	5.84B	5.84B	61.32K	-119K	-257K	-30K	517K	0	0	0
Other Non-Cash Items	-5.84B	-5.84B	58.74K	3.94M	3.52M	4M	2.4M	4.11M	2.22M	2.58M
Working Capital Changes	2.07M	8.77M	8.56M	27.76M	25.19M	-19.76M	-12.22M	-1.65M	-84.66M	-109.3M
Change in Receivables	-100.5K	102.17K	-24.62K	14K	-11K	-6K	-1.39M	1.39M	-51.09M	-78.09M
Change in Inventory	0	0	0	0	11K	6K	-15.99M	0	-36.94M	-66.85M
Change in Payables	5.47M	6.49M	11.02M	10.96M	-4.79M	11.63M	15.99M	-11.01M	192K	0
Cash from Investing+	-24.69M	26.55M	-8.21M	1.18M	-718K	-24.51M	-332K	-20.01M	-50.65M	-1.04M
Capital Expenditures	-42.22K	-343.99K	-2.23K	-90K	-131K	-357K	-401K	-14K	0	-45K
CapEx % of Revenue	0.28%	2.26%	0.01%	0.59%	0.86%	2.35%	0.06%	0.01%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.64M	26.89M	-8.21M	1.27M	-587K	-24.15M	69K	-20M	0	0
Cash from Financing+	68.72M	5.02M	133.66M	113.64M	204.21M	679.83M	41.42M	-391K	72.7M	128.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	963.17K	-13.47K	0	0	-795K	147K	-800K	0	1.41M	25K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-44.73M	-61.94M	-93.77M	-129.01M	-132.94M	-214.86M	-296.04M	-176.18M	-31.41M	-40.56M
FCF Margin %	-293.56%	-406.45%	-615.34%	-848.78%	-874.59%	-1413.58%	-44.26%	-63.26%	-0.13%	-0.12%
FCF Growth %	-0.28%	-0.38%	-0.51%	-0.38%	-0.03%	-0.62%	-0.38%	0.4%	0.82%	-0.29%
FCF per Share	-0.98	-1.26	-1.51	-1.71	-1.50	-1.86	-2.24	-1.30	-0.21	-0.25
FCF Conversion (FCF/Net Income)	0.71x	0.79x	0.79x	0.74x	0.77x	0.77x	0.85x	0.79x	-2.48x	-1.73x
Interest Paid	0	0	0	0	0	0	0	0	0	18.47M
Taxes Paid	0	0	0	0	0	0	0	0	0	500K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-69.3%	-113.87%	-230.36%	-381.16%	-551.85%	-100.14%	-92.03%	-151.36%	11.57%	12.21%
Return on Invested Capital (ROIC)	-132.76%	-205.55%	-835.68%	-	-	-	-2052.2%	-578%	14.22%	13.25%
Gross Margin	100%	58.68%	45.95%	42.11%	100%	100%	88.19%	90.48%	93.95%	88.3%
Net Margin	-41310.04%	-51353.45%	-77749.86%	-114132.89%	-113730.92%	-183803.29%	-5204.08%	-8036.34%	5.42%	7.11%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	1.06x	0.08x	0.33x	1.42x	0.69x	1.14x
Interest Coverage	-64.95x	-	-104.18x	-100.58x	-31.98x	-43.23x	-61.15x	-21.42x	1.64x	1.75x
FCF Conversion	0.71x	0.79x	0.79x	0.74x	0.77x	0.77x	0.85x	0.79x	-2.48x	-1.73x
Revenue Growth	0%	0%	0%	-0.25%	0%	0%	4300.66%	-58.36%	8290.02%	40.8%

Revenue by Segment

	2021	2022	2023	2024
Product	-	-	92M	313.73M
Product Growth	-	-	-	240.99%
Milestone	-	-	-	12.5M
Milestone Growth	-	-	-	-
Other Revenue	-	-	1.5M	1.82M
Other Revenue Growth	-	-	-	21.21%
Royalty	-	-	-	801K
Royalty Growth	-	-	-	-
License Revenue	-	-	140.15M	152K
License Revenue Growth	-	-	-	-99.89%
Product revenue, net	6.54M	2.63M	-	-
Product revenue, net Growth	-	-59.72%	-	-
License revenue	152K	152K	-	-
License revenue Growth	-	0.00%	-	-

Revenue by Geography

	2021	2022	2023	2024
Worldwide	-	-	92M	313.73M
Worldwide Growth	-	-	-	240.99%
International	-	-	3.22M	3.71M
International Growth	-	-	-	15.10%

Frequently Asked Questions

Valuation & Price

TG Therapeutics, Inc. (TGTX) has a price-to-earnings (P/E) ratio of 204.7x. This suggests investors expect higher future growth.

Growth & Financials

TG Therapeutics, Inc. (TGTX) reported $454.1M in revenue for fiscal year 2024.

TG Therapeutics, Inc. (TGTX) grew revenue by 40.8% over the past year. This is strong growth.

Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $60.5M in net income for fiscal year 2024 (7.1% net margin).

Dividend & Returns

TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 12.2%. This is reasonable for most industries.

TG Therapeutics, Inc. (TGTX) had negative free cash flow of $59.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

TG Therapeutics, Inc. (TGTX) 10-Year Financial Performance & Capital Metrics

TGTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $329M +40.8%
EBITDA $42M +100.5%
Net Income $23M +84.5%
EPS (Diluted) 0.15 +75.8%
Gross Margin 88.3% -6.0%
EBITDA Margin 12.83% +42.4%
Operating Margin 12.74% +44.3%
Net Margin 7.11% +31.1%
ROE 12.21% +5.6%
ROIC 13.25% -6.8%
Debt/Equity 1.14 +65.3%
Interest Coverage 1.75 +6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 364.6%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Expensive at 22.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y115.49%

5Y364.59%

3Y266.39%

TTM30.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-36.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-38.15%

ROCE

10Y Avg-122.62%

5Y Avg-48.95%

3Y Avg-25.05%

Latest10.99%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	152.38K	152.38K	152.38K	152K	152K	152K	6.69M	2.79M	233.66M	329M
Revenue Growth %	0%	0%	0%	-0%	0%	0%	43.01%	-0.58%	82.9%	0.41%
Cost of Goods Sold+	0	62.96K	82.36K	88K	0	0	790K	265K	14.13M	38.49M
COGS % of Revenue	-	0.41%	0.54%	0.58%	-	-	0.12%	0.1%	0.06%	0.12%
Gross Profit+	152.38K	89.42K	70.03K	64K	152K	152K	5.9M	2.52M	219.53M	290.52M
Gross Margin %	1%	0.59%	0.46%	0.42%	1%	1%	0.88%	0.9%	0.94%	0.88%
Gross Profit Growth %	0%	-0.41%	-0.22%	-0.09%	1.38%	0%	37.81%	-0.57%	86.12%	0.32%
Operating Expenses+	63.33M	79.12M	118.86M	174.55M	169.21M	273.75M	350.67M	220.84M	198.9M	248.59M
OpEx % of Revenue	415.62%	519.23%	780.05%	1148.37%	1113.2%	1800.96%	52.42%	79.29%	0.85%	0.76%
Selling, General & Admin	15.63M	9.89M	16.33M	15.16M	15.03M	107.85M	128.09M	95.48M	122.71M	154.3M
SG&A % of Revenue	102.54%	64.9%	107.17%	99.74%	98.86%	709.54%	19.15%	34.29%	0.53%	0.47%
Research & Development	43.45M	66.49M	96.89M	153.79M	154.18M	165.9M	222.58M	125.35M	76.19M	94.29M
R&D % of Revenue	285.11%	436.34%	635.82%	1011.8%	1014.34%	1091.42%	33.28%	45.01%	0.33%	0.29%
Other Operating Expenses	1.03M	393.2K	-58.74K	61K	0	0	0	0	0	0
Operating Income+	-63.18M	-78.97M	-118.71M	-174.4M	-169.06M	-273.59M	-344.77M	-218.32M	20.63M	41.93M
Operating Margin %	-414.62%	-518.23%	-779.05%	-1147.37%	-1112.2%	-1799.96%	-51.54%	-78.39%	0.09%	0.13%
Operating Income Growth %	-0.13%	-0.25%	-0.5%	-0.47%	0.03%	-0.62%	-0.26%	0.37%	1.09%	1.03%
EBITDA+	-63.16M	-78.91M	-118.63M	-174.31M	-168.77M	-273.22M	-344.28M	-217.8M	21.06M	42.21M
EBITDA Margin %	-414.52%	-517.82%	-778.51%	-1146.79%	-1110.35%	-1797.5%	-51.47%	-78.21%	0.09%	0.13%
EBITDA Growth %	-0.13%	-0.25%	-0.5%	-0.47%	0.03%	-0.62%	-0.26%	0.37%	1.1%	1%
D&A (Non-Cash Add-back)	15.45K	62.96K	82.36K	88K	282K	374K	494K	515K	423K	280K
EBIT	-63.18M	-78.97M	-117.63M	-172.6M	-167.58M	-273.05M	-342.46M	-213.62M	25.68M	49.62M
Net Interest Income+	-798.08K	323K	-845K	-877K	-5.29M	-6.33M	-5.64M	-10.19M	-12.62M	-24.03M
Interest Income	174.65K	323.03K	294.48K	857K	0	0	0	0	0	0
Interest Expense	972.74K	0	1.14M	1.73M	5.29M	6.33M	5.64M	10.19M	12.62M	24.03M
Other Income/Expense	231.37K	716K	235.99K	918K	-3.82M	-5.79M	-3.33M	-5.5M	-7.57M	-16.34M
Pretax Income+	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	13.06M	25.59M
Pretax Margin %	-413.1%	-513.53%	-777.5%	-1141.33%	-1137.31%	-1838.03%	-52.04%	-80.36%	0.06%	0.08%
Income Tax+	-231.37K	-716.23K	-235.74K	-918K	0	0	0	0	390K	2.21M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	0.97%	0.91%
Net Income+	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	12.67M	23.38M
Net Margin %	-413.1%	-513.53%	-777.5%	-1141.33%	-1137.31%	-1838.03%	-52.04%	-80.36%	0.05%	0.07%
Net Income Growth %	-0.13%	-0.24%	-0.51%	-0.46%	0%	-0.62%	-0.25%	0.36%	1.06%	0.85%
Net Income (Continuing)	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-223.81M	12.67M	23.38M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.38	-1.60	-1.91	-2.30	-1.96	-2.42	-2.63	-1.46	0.09	0.15
EPS Growth %	0.16%	-0.16%	-0.19%	-0.2%	0.15%	-0.23%	-0.09%	0.44%	1.06%	0.76%
EPS (Basic)	-1.38	-1.60	-1.91	-2.30	-1.96	-2.42	-2.63	-1.46	0.09	0.16
Diluted Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	148.51M	160.34M
Basic Shares Outstanding	45.65M	49.04M	62.07M	75.47M	88.37M	115.33M	132.22M	135.41M	141.96M	145.32M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	86.87M	50.86M	93.32M	79.03M	149.15M	611.74M	330.96M	168.27M	317.94M	566.36M
Cash & Short-Term Investments	102.42M	44.97M	84.83M	68.81M	140.44M	605.43M	314.76M	161.68M	217.51M	311M
Cash Only	55.06M	25.03M	56.72M	41.96M	112.64M	553.44M	298.89M	102.3M	92.93M	179.89M
Short-Term Investments	22.17M	19.85M	28M	26.85M	27.8M	51.99M	15.88M	59.37M	124.58M	131.11M
Accounts Receivable	186.02K	83.85K	108.47K	95K	0	0	1.39M	0	51.09M	129.19M
Days Sales Outstanding	445.58	200.85	259.81	228.13	-	-	75.79	-	79.81	143.32
Inventory	-16.04M	5.59M	7.95M	9.69M	0	0	0	0	39.82M	110.46M
Days Inventory Outstanding	-	32.44K	35.22K	40.2K	-	-	-	-	1.03K	1.05K
Other Current Assets	308.33K	216.4K	328.32K	344K	611K	1.08M	2.88M	2.36M	5.34M	15.72M
Total Non-Current Assets+	26.6M	3.92M	4.06M	4.58M	13.86M	13.9M	48.66M	25.3M	11.64M	11.33M
Property, Plant & Equipment	47.12K	2.37M	2.68M	2.54M	11.81M	11.84M	11.07M	10.82M	8.05M	7.15M
Fixed Asset Turnover	3.23x	0.06x	0.06x	0.06x	0.01x	0.01x	0.60x	0.26x	29.03x	46.01x
Goodwill	799.39K	799.39K	799.39K	799K	799K	799K	799K	799K	799K	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	25M	583.21K	587.29K	1.24M	0	0	35.53M	12.4M	0	808K
Other Non-Current Assets	750.33K	747.58K	587.29K	1.24M	1.25M	1.26M	1.26M	1.27M	2.79M	3.37M
Total Assets+	113.47M	54.78M	97.38M	83.62M	163.01M	625.64M	379.63M	193.57M	329.59M	577.69M
Asset Turnover	0.00x	0.00x	0.00x	0.00x	0.00x	0.00x	0.02x	0.01x	0.71x	0.57x
Asset Growth %	0.31%	-0.52%	0.78%	-0.14%	0.95%	2.84%	-0.39%	-0.49%	0.7%	0.75%
Total Current Liabilities+	10.53M	16.88M	27.96M	38.85M	84.45M	87.55M	65.38M	53.2M	53.72M	90.68M
Accounts Payable	9.35M	15.27M	25.88M	36.38M	0	0	0	0	0	0
Days Payables Outstanding	-	88.51K	114.69K	150.88K	-	-	-	-	-	-
Short-Term Debt	211.55K	68.88K	127.61K	67K	0	22.18M	975K	0	0	0
Deferred Revenue (Current)	152.38K	152.38K	152.38K	152K	0	0	0	0	152K	1000K
Other Current Liabilities	0	0	0	0	82.83M	63.71M	62.97M	51.62M	52.12M	78.11M
Current Ratio	8.25x	3.01x	3.34x	2.03x	1.77x	6.99x	5.06x	3.16x	5.92x	6.25x
Quick Ratio	9.77x	2.68x	3.05x	1.78x	1.77x	6.99x	5.06x	3.16x	5.18x	5.03x
Cash Conversion Cycle	-	-55.88K	-79.21K	-110.46K	-	-	-	-	-	-
Total Non-Current Liabilities+	1.37M	2.04M	2.43M	20.73M	39.95M	18.74M	77.09M	81.78M	115.36M	264.65M
Long-Term Debt	0	0	0	0	28.97M	7.72M	66.79M	71.14M	100.12M	244.43M
Capital Lease Obligations	0	0	0	0	10.22M	10.41M	9.85M	10.34M	9.23M	8.13M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	816.26K	1.36M	19.81M	0	0	0	0	0	0
Total Liabilities	113.47M	54.78M	97.38M	59.58M	124.4M	106.29M	142.48M	134.99M	169.09M	355.33M
Total Debt+	211.55K	68.88K	127.61K	67K	40.8M	41.98M	79.05M	83.06M	110.8M	253.72M
Net Debt	-54.85M	-24.96M	-56.59M	-41.89M	-71.83M	-511.46M	-219.84M	-19.24M	17.86M	73.83M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	1.06x	0.08x	0.33x	1.42x	0.69x	1.14x
Debt / EBITDA	-	-	-	-	-	-	-	-	5.26x	6.01x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	0.85x	1.75x
Interest Coverage	-64.95x	-	-104.18x	-100.58x	-31.98x	-43.23x	-61.15x	-21.42x	1.64x	1.75x
Total Equity+	101.57M	35.87M	66.99M	24.04M	38.62M	519.35M	237.15M	58.59M	160.5M	222.36M
Equity Growth %	0.27%	-0.65%	0.87%	-0.64%	0.61%	12.45%	-0.54%	-0.75%	1.74%	0.39%
Book Value per Share	2.23	0.73	1.08	0.32	0.44	4.50	1.79	0.43	1.08	1.39
Total Shareholders' Equity	101.57M	35.87M	66.99M	24.04M	38.62M	519.35M	237.15M	58.59M	160.5M	222.36M
Common Stock	54.09K	56.82K	73.18K	84K	109K	141K	143K	146K	151K	156K
Retained Earnings	-158.13M	-236.39M	-354.86M	-528.35M	-701.22M	-980.6M	-1.33B	-1.53B	-1.55B	-1.53B
Treasury Stock	-234.34K	-234.34K	-234.34K	-234K	-234K	-234K	-234K	-234K	-234K	-8.99M
Accumulated OCI	6	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-44.69M	-61.59M	-93.76M	-128.93M	-132.81M	-214.51M	-295.63M	-176.17M	-31.41M	-40.52M
Operating CF Margin %	-293.28%	-404.19%	-615.32%	-848.19%	-873.72%	-1411.23%	-44.2%	-63.26%	-0.13%	-0.12%
Operating CF Growth %	-0.27%	-0.38%	-0.52%	-0.38%	-0.03%	-0.62%	-0.38%	0.4%	0.82%	-0.29%
Net Income	-62.95M	-78.25M	-118.48M	-173.48M	-172.87M	-279.38M	-348.1M	-198.34M	12.67M	23.38M
Depreciation & Amortization	15.45K	62.96K	82.36K	88K	282K	374K	494K	515K	423K	280K
Stock-Based Compensation	15.7M	7.51M	15.95M	12.89M	11.34M	80.29M	61.27M	19.18M	37.93M	42.54M
Deferred Taxes	5.84B	5.84B	61.32K	-119K	-257K	-30K	517K	0	0	0
Other Non-Cash Items	-5.84B	-5.84B	58.74K	3.94M	3.52M	4M	2.4M	4.11M	2.22M	2.58M
Working Capital Changes	2.07M	8.77M	8.56M	27.76M	25.19M	-19.76M	-12.22M	-1.65M	-84.66M	-109.3M
Change in Receivables	-100.5K	102.17K	-24.62K	14K	-11K	-6K	-1.39M	1.39M	-51.09M	-78.09M
Change in Inventory	0	0	0	0	11K	6K	-15.99M	0	-36.94M	-66.85M
Change in Payables	5.47M	6.49M	11.02M	10.96M	-4.79M	11.63M	15.99M	-11.01M	192K	0
Cash from Investing+	-24.69M	26.55M	-8.21M	1.18M	-718K	-24.51M	-332K	-20.01M	-50.65M	-1.04M
Capital Expenditures	-42.22K	-343.99K	-2.23K	-90K	-131K	-357K	-401K	-14K	0	-45K
CapEx % of Revenue	0.28%	2.26%	0.01%	0.59%	0.86%	2.35%	0.06%	0.01%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.64M	26.89M	-8.21M	1.27M	-587K	-24.15M	69K	-20M	0	0
Cash from Financing+	68.72M	5.02M	133.66M	113.64M	204.21M	679.83M	41.42M	-391K	72.7M	128.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	963.17K	-13.47K	0	0	-795K	147K	-800K	0	1.41M	25K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-44.73M	-61.94M	-93.77M	-129.01M	-132.94M	-214.86M	-296.04M	-176.18M	-31.41M	-40.56M
FCF Margin %	-293.56%	-406.45%	-615.34%	-848.78%	-874.59%	-1413.58%	-44.26%	-63.26%	-0.13%	-0.12%
FCF Growth %	-0.28%	-0.38%	-0.51%	-0.38%	-0.03%	-0.62%	-0.38%	0.4%	0.82%	-0.29%
FCF per Share	-0.98	-1.26	-1.51	-1.71	-1.50	-1.86	-2.24	-1.30	-0.21	-0.25
FCF Conversion (FCF/Net Income)	0.71x	0.79x	0.79x	0.74x	0.77x	0.77x	0.85x	0.79x	-2.48x	-1.73x
Interest Paid	0	0	0	0	0	0	0	0	0	18.47M
Taxes Paid	0	0	0	0	0	0	0	0	0	500K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-69.3%	-113.87%	-230.36%	-381.16%	-551.85%	-100.14%	-92.03%	-151.36%	11.57%	12.21%
Return on Invested Capital (ROIC)	-132.76%	-205.55%	-835.68%	-	-	-	-2052.2%	-578%	14.22%	13.25%
Gross Margin	100%	58.68%	45.95%	42.11%	100%	100%	88.19%	90.48%	93.95%	88.3%
Net Margin	-41310.04%	-51353.45%	-77749.86%	-114132.89%	-113730.92%	-183803.29%	-5204.08%	-8036.34%	5.42%	7.11%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	1.06x	0.08x	0.33x	1.42x	0.69x	1.14x
Interest Coverage	-64.95x	-	-104.18x	-100.58x	-31.98x	-43.23x	-61.15x	-21.42x	1.64x	1.75x
FCF Conversion	0.71x	0.79x	0.79x	0.74x	0.77x	0.77x	0.85x	0.79x	-2.48x	-1.73x
Revenue Growth	0%	0%	0%	-0.25%	0%	0%	4300.66%	-58.36%	8290.02%	40.8%

Revenue by Segment

	2021	2022	2023	2024
Product	-	-	92M	313.73M
Product Growth	-	-	-	240.99%
Milestone	-	-	-	12.5M
Milestone Growth	-	-	-	-
Other Revenue	-	-	1.5M	1.82M
Other Revenue Growth	-	-	-	21.21%
Royalty	-	-	-	801K
Royalty Growth	-	-	-	-
License Revenue	-	-	140.15M	152K
License Revenue Growth	-	-	-	-99.89%
Product revenue, net	6.54M	2.63M	-	-
Product revenue, net Growth	-	-59.72%	-	-
License revenue	152K	152K	-	-
License revenue Growth	-	0.00%	-	-

Revenue by Geography

	2021	2022	2023	2024
Worldwide	-	-	92M	313.73M
Worldwide Growth	-	-	-	240.99%
International	-	-	3.22M	3.71M
International Growth	-	-	-	15.10%

Frequently Asked Questions

Valuation & Price

TG Therapeutics, Inc. (TGTX) has a price-to-earnings (P/E) ratio of 204.7x. This suggests investors expect higher future growth.

Growth & Financials

TG Therapeutics, Inc. (TGTX) reported $454.1M in revenue for fiscal year 2024.

TG Therapeutics, Inc. (TGTX) grew revenue by 40.8% over the past year. This is strong growth.

Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $60.5M in net income for fiscal year 2024 (7.1% net margin).

Dividend & Returns

TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 12.2%. This is reasonable for most industries.

TG Therapeutics, Inc. (TGTX) had negative free cash flow of $59.2M in fiscal year 2024, likely due to heavy capital investments.